CONCLUSIONS: Despite its rare occurrence, our findings confirm sRCC variant histology being a strong predictor for inferior outcomes in mRCC treated with targeted therapies. Our findings support the thesis of a reduced response to antiangiogenic therapies due to an increased resistance in sRCC compared to ccRCC. METHODS: We collected data of 398 patients with mRCC at our academic center. Patients with previous immunotherapy, metastasectomy only treatment and missing data were excluded. A final cohort of 262 pts. remained for analyses. Patients received either CN and subsequent TKI or immediate TKI treatement. Differences in patient characteristics and outcomes were analyzed using descriptive analytics, Kaplan-Meier estimations and uni-and multivariable Cox regression proportional with regards to CN administration.
INTRODUCTION AND OBJECTIVES:
Complete surgical resection of metastases from renal cell carcinoma (RCC) is associated with prolonged disease-free survival and occasional long-term cure in selected patients. However, the majority of existing data is from the immunotherapy era. Whether complete metastasectomy (CM) remains beneficial among contemporary patients, with more effective systemic therapies available, has not been well studied. Therefore, we examined outcomes of patients treated with CM in the era of targeted therapy and checkpoint blockade availability.
METHODS: We queried our institutional nephrectomy registry to identify patients treated with radical or partial nephrectomy for unilateral, sporadic RCC whose first occurrence of distant metastases occurred between 2006-2017. Patients were classified according to whether or not they underwent complete surgical resection of all sites of metastatic disease. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method, and associations of clinicopathologic features with time to death from RCC were assessed using Cox proportional hazards models.
RESULTS: A total of 586 patients were identified, including 158 treated with CM. Median follow up after diagnosis of metastases was 3.9 years, during which time 403 patients died, including 345 from RCC. CM patients were more likely to have metastases diagnosed > 1 year after nephrectomy and to have a solitary site of metastasis than those without CM (p<0.001 for both). Of the CM patients, 147 (93%) did not require systemic therapy (targeted therapy or immunotherapy) for their index metastatic lesion(s). Two-year CSS was significantly greater for patients with CM than for those without (84% vs. 54%, p<0.001). After adjusting for age, sex, and the timing, number, and location of metastases, CM was associated with a significantly reduced likelihood of death from RCC (HR 0.42, 95% CI 0.31-0.57, p<0.001).
CONCLUSIONS: Complete surgical resection of metastases from RCC is associated with improved CSS in the contemporary era. CM should continue to be considered a viable treatment option for select patients with metastatic RCC.
Source of Funding: None

MP25-07 NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE BIOMARKER FOR RESPONSE TO NIVOLUMAB IN ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Yukari Bando*, Mariko Sakamoto, Yasuyoshi Okamura, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa, Kobe, Japan INTRODUCTION AND OBJECTIVES: Nivolumab, a programmed cell death protein-1 (PD-1) antibody, is one of the most effective therapeutic agents for advanced renal cell carcinoma (RCC). Biomarkers predicting response to this treatment are needed to better select patients most likely to benefit. Neutrophil-to-lymphocyte ratio (NLR) is a prognostic and predictive biomarker in various malignancies. We sought to identify predictive markers of nivolumab response in patients with advanced RCC, including NLR.
METHODS: A retrospective review was performed for 109 consecutive patients with metastatic or unresectable RCC treated with nivolumab from December 2016 to September 2018 at our institution and seven related institutions. Landmark analysis was conducted to explore the prognostic value of NLR at baseline on overall survival. Cox and logistic regression models allowed for adjustment of age, platelet count, IMDC risk classification, experience of cytoreductive nephrectomy, histological type, number of prior therapies, NLR at baseline, and the occurrence of immune-related adverse events (irAE).
RESULTS: IMDC risk groups were: 15.6% favorable, 56.9% intermediate, and 27.5% poor risk. The treatment line of nivolumab was 2nd in 44, 3rd in 34, and 4th line or later in 31 patients. The best response to nivolumab was as follows: complete response in 4 patients (4.1%), partial response in 25 patients (26.0%), stable disease in 35 patients (36.5%), and progression disease in 32 patients (33.3%). Median overall survival (OS) after nivolumab was not reached, median progression-free survival was 8 months, and median time to treatment failure was 6 months. Regarding irAE, 51 symptoms were observed in 31 patients. NLR at baseline (NLR>3.3) was found to be related to OS with nivolumab, whereas there were no significant relationships with age, platelet count, IMDC risk classification, experience of cytoreductive nephrectomy, histological type, number of prior therapies, and the occurrence of irAE.
CONCLUSIONS: NLR at baseline was associated with OS with nivolumab in Asian patients with metastatic RCC treated with nivolumab.
Source of Funding: None.
MP25-08 THE EFFICACY AND SAFETY OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE
Kaifang Ma*, Kan Gong, Baoan Hong, Haibiao Xie, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: von Hippel-Lindau (VHL) disease is an autosomal-dominant, multi-organ, familial neoplastic syndrome. To date, studies about targeted therapy in Chinese patients associated with von Hippel-Lindau disease are limited. In this study, we aimed to evaluate the efficacy and safety of four different tyrosine kinase inhibitors in patients with VHL disease.
METHODS: In this retrospective study, patients who diagnosed with VHL disease and received targeted therapy were recruited from Peking University First Hospital. Clinical data were obtained through interviews with patients or living family members and review of medical records. Patients were treated with four different tyrosine kinase inhibitors, respectively, including sunitinib (n[12), sorafenib (n[11), axitinib (n[6) and pazopanib (n[3). Assessments of clinical response and degrees of tumor changes were performed according to the Response Evaluation Criteria in Sold Tumor (RECIST). Diverse adverse events related to the treatment of tyrosine kinase inhibitors were evaluated.
RESULTS: From July 2009 to April 2018, 39 patients with genetically verified or clinical manifestations consistent with von HippelLindau disease, of whom 32 patients eligible to this study. The mean time of targeted therapy was 27.8 months (range 3-87 months) and mean follow-up time was 29.1AE26.2 months (range 3-93 months). According to RECIST, 8 (25%) of 32 patients showed partial response to therapy, 16 (50%) of 32 patients achieved with stable disease and eight patients progressed. Lesion sites response were observed in 11 (31%) of 36 renal cell carcinomas, three (23%) of 13 renal cysts, four (27%) of 15 pancreatic lesions and one (20%) of five central nervous system hemangioblastomas. The study showed that the sizes of RCC (P[0.00013), renal cyst (P[0.027) and pancreatic lesion (P[0.003) were significant decreased after targeted therapy. The most common side-effects observed in this study including handfoot syndrome, diarrhea, alopecia, back pain, thrombocytopenia and fatigue. Dosage reductions were needed in 13 patients and often occurred in the sunitinib and sorafenib treatment group. Treatmentrelated serious adverse reactions included peridental abscess, hyperbilirubinemia and one case appeared perforation of nasal septum due to epistaxis repeatedly.
CONCLUSIONS: Tyrosine kinase inhibitors are effective in von Hippel-Lindau disease with acceptable side-effects, which are favorable options for VHL patients. Further evaluation of TKIs in patients with VHL disease in larger prospective studies is warranted. 
MP25-09 EARLY FLARE-RESPONSE OF C-REACTIVE PROTEIN IS ASSOCIATED WITH EFFICACY OF NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Shohei Fukuda*, Kazutaka Saito, Yosuke Yasuda, Tokyo, Japan; Takahiko Soma, Saitama, Japan; Masahiro Toide, Hiroshi Fukushima, Shingo Moriyama, Sho Uehara, Tokyo, Japan; Naotaka Fukui, Saitama, Japan; Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Tokyo, Japan; Yukio Kageyama, Saitama, Japan; Yasuhisa Fujii, Tokyo, Japan INTRODUCTION AND OBJECTIVES: C-reactive protein (CRP), a representative systemic inflammatory response, has been shown to be a potential biomarker for renal cell carcinoma (RCC). The dynamic change of CRP levels, CRP kinetics, is a predictive factor for survival of patients with metastatic RCC (mRCC) in the tyrosine kinase inhibitor (TKI) era. In this study, we investigated the impact of the early CRP kinetics on the efficacy of nivolumab in patients with mRCC.
METHODS: A total of 32 patients (25 males and 7 females) were treated with nivolumab for mRCC from 2016 to 2018 at our institutions. Patients were divided into three groups according to their early CRP kinetics ( Fig.1) : patients whose CRP levels had increased to more than double from baseline within 1 month after initiation of nivolumab (flare) and then decreased to a lower value than baseline within 3 months (CRP flare-responder), patients whose CRP levels decreased by !30% from baseline within 3 months without "flare" (CRP responder), and the remaining patients (non-CRP responder). Maximum tumor shrinkage and objective response rate were evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The association of the early CRP kinetics and radiological responses to nivolumab was assessed.
RESULTS: The median follow up period and number of administration cycles were 5 months (range 1-18) and 8 cycles (1-28), respectively. The median baseline CRP level was 30 mg/L (0.2-169). Among all patients, CRP flare-responders, CRP responders and non-CRP responders were 8 (25%), 12 (37.5%) and 12 (37.5%) patients, respectively. Nine patients (28%) died of mRCC. During the follow-up period, 6 (19%), 19 (59%) and 7 (22%) patients experienced partial response, stable disease and progressive disease, respectively. The maximum change in target lesion from baseline of CRP flareresponder, CRP-responder and non-CRP responder group were -35%, -8% and þ19% on average, respectively (p<0.001) (Fig. 2) . Objective response rates of these three groups were 63%, 8% and 0%, respectively (p[0.001).
